✦ LIBER ✦

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector

✍ Scribed by Kay, Mark A.; Manno, Catherine S.; Ragni, Margaret V.; Larson, Peter J.; Couto, Linda B.; McClelland, Alan; Glader, Bertil; Chew, Amy J.; J Tai, Shing; Herzog, Roland W.

Book ID: 109827756
Publisher: Nature Publishing Group
Year: 2000
Tongue: English
Weight: 342 KB
Volume: 24
Category: Article
ISSN: 1061-4036
DOI: 10.1038/73464

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intravenous administration of an AAV-2 v

Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B

✍ Harding, T C; Koprivnikar, K E; Tu, G H; Zayek, N; Lew, S; Subramanian, A; Sivak 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 288 KB

Pharmacokinetic study of a high-purity f

Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols®) with a 6-month follow up in previously treated patients with severe haemophilia B

✍ J. A. AZNAR; N. CABRERA; M. MATYSIAK; K. ZAWILSKA; L. GERCHEVA; A. ANTONOV; M. M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

An open clinical study assessing the eff

An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B

✍ T. LISSITCHKOV; M. MATYSIAK; K. ZAWILSKA; L. GERCHEVA; A. ANTONOV; M. MONTAÑES; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Clinical efficacy, safety and pharmacoki

Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine® in previously treated patients with severe haemophilia B

✍ M. SERBAN; A. B. SKOTNICKI; M. COLOVIC; C. JINCA; A. KLUKOWSKA; P. LAGUNA; D. M. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Clinical evaluation of an advanced categ

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A

✍ M. D. Tarantino; P. W. Collins; C. R. M. Hay; A.D. Shapiro; R. A. Gruppo; E. Ber 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB

Bulky disease is an adverse prognostic f

Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma

✍ Richard B. Wilder; Maria A. Rodriguez; Chul S. Ha; Barbara Pro; Mark A. Hess; Fe 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB